Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy
Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy
复制标题
基质金属蛋白酶9功能多态性与局部晚期鼻咽癌放化疗患者生存率的关系
DOI：
10.1007/s12032-013-0685-6
复制
发表时间：
2013-12-01
期刊：
影响因子：
3.4
通讯作者：
Mai, Hai-Qiang
中科院分区：
文献类型：
--
作者：
Liu, Huai;Huang, Pei-Yu;Mai, Hai-Qiang
探讨主要基质金属蛋白酶（MMP）基因多态性对接受放化疗的局部晚期鼻咽癌（NPC）患者的预后作用。前瞻性招募了 421 名连续的 NPC 患者。随机选择 200 名患者作为训练队列，其余 221 名患者作为验证队列。通过连接酶检测反应-PCR对MMP-1、2、3、7、8和9基因的12个多态性进行基因分型。 MMP-9 rs2250889 PR/RR（HR = 2.287，95% CI 1.400-3.735）和rs17576 RQ/QQ（HR = 2.347，95% CI 1.431-3.849）基因型与训练队列中死亡风险增加显着相关。验证队列分析证实了这些结果（rs2250889：HR = 2.231，95% CI 1.281-3.886；rs17576：HR = 2.987，95% CI 1.674-5.330）。多变量分析显示rs17576（HR = 2.284，95% CI 1.123-4.643，P = 0.023）仍然是一个独立的预后因素。 MMP-9 rs17576 是接受放化疗的局部晚期 NPC 患者的一种新型独立预后标志物。
To investigate the prognostic role of major matrix metalloproteinase (MMP) gene polymorphisms in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with chemoradiotherapy. Four hundred twenty-one consecutive NPC patients were prospectively recruited. Two hundred patients were randomly selected as the training cohort, and the remaining 221 patients were the validation cohort. Twelve polymorphisms in the MMP-1, 2, 3, 7, 8, and 9 genes were genotyped by ligase detection reaction-PCR. MMP-9 rs2250889 PR/RR (HR = 2.287, 95 % CI 1.400-3.735) and rs17576 RQ/QQ (HR = 2.347, 95 % CI 1.431-3.849) genotypes were significantly related with increased death risk in the training cohort. Analysis of the validation cohort confirmed these results (rs2250889: HR = 2.231, 95 % CI 1.281-3.886; rs17576: HR = 2.987, 95 % CI 1.674-5.330). Multivariate analysis showed that rs17576 (HR = 2.284, 95 % CI 1.123-4.643, P = 0.023) was still an independent prognostic factor. The MMP-9 rs17576 is a novel independent prognostic marker in patients with locoregionally advanced NPC treated with chemoradiotherapy.